Mo1796 TUMOR NECROSIS FACTOR ANTAGONISTS ARE SUPERIOR TO ANTI-INTEGRIN AND ANTI-IL-12/23 THERAPIES FOR PREVENTING POSTOPERATIVE RECURRENCE IN ADULT CROHN'S DISEASE PATIENTS REQUIRING POSTOPERATIVE THERAPY